Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical gemcitabine for superficial bladder cancer after TUR
ACTRN12607000160437Phase 2Recruiting
- Sponsor
- St George Hospital
- Start
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine in bladder cancer and transitional cell carcinoma (TCC) (2 arms), sponsored by St George Hospital. Primary endpoint: Response rate / recurrence rate following treatment. Started Jan 2005; status: recruiting.
02
Drugs
gemcitabine
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ACTRN12607000160437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000160437.